MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia

Dasatinib (BMS-354825) is a FDA-approved multitargeted kinase inhibitor of BCR/ABL and Src kinases. It is now used in the treatment of chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapies, including imatinib. Here we report a novel effect of dasatinib on inducing the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Yanfen, Zhong, Like, Lin, Meihua, Zhou, Xinglu, Jing, Hui, Ying, Meidan, Luo, Peihua, Yang, Bo, He, Qiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692534/
https://www.ncbi.nlm.nih.gov/pubmed/23825585
http://dx.doi.org/10.1371/journal.pone.0066915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692534/
https://www.ncbi.nlm.nih.gov/pubmed/23825585
http://dx.doi.org/10.1371/journal.pone.0066915

Ejemplares similares